Molecular imaging and fusion targeted biopsy of the prostate

Baowei Fei, Peter T. Nieh, Viraj A. Master, Yun Zhang, Adeboye O. Osunkoya, David M. Schuster

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose: This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods: Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results: Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion: Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.

Original languageEnglish (US)
Pages (from-to)29-43
Number of pages15
JournalClinical and Translational Imaging
Volume5
Issue number1
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Molecular Imaging
Prostate
Prostatic Neoplasms
Biopsy
Magnetic Resonance Imaging
Positron-Emission Tomography
Technology
Three-Dimensional Imaging
Selection Bias
Early Detection of Cancer
Research
PubMed
Autopsy
Databases

Keywords

  • Image registration
  • Image segmentation
  • Magnetic resonance imaging (MRI)
  • Molecular imaging
  • Positron emission tomography (PET)
  • Prostate cancer
  • Targeted biopsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Fei, B., Nieh, P. T., Master, V. A., Zhang, Y., Osunkoya, A. O., & Schuster, D. M. (2017). Molecular imaging and fusion targeted biopsy of the prostate. Clinical and Translational Imaging, 5(1), 29-43. https://doi.org/10.1007/s40336-016-0214-7

Molecular imaging and fusion targeted biopsy of the prostate. / Fei, Baowei; Nieh, Peter T.; Master, Viraj A.; Zhang, Yun; Osunkoya, Adeboye O.; Schuster, David M.

In: Clinical and Translational Imaging, Vol. 5, No. 1, 01.02.2017, p. 29-43.

Research output: Contribution to journalReview article

Fei, B, Nieh, PT, Master, VA, Zhang, Y, Osunkoya, AO & Schuster, DM 2017, 'Molecular imaging and fusion targeted biopsy of the prostate', Clinical and Translational Imaging, vol. 5, no. 1, pp. 29-43. https://doi.org/10.1007/s40336-016-0214-7
Fei, Baowei ; Nieh, Peter T. ; Master, Viraj A. ; Zhang, Yun ; Osunkoya, Adeboye O. ; Schuster, David M. / Molecular imaging and fusion targeted biopsy of the prostate. In: Clinical and Translational Imaging. 2017 ; Vol. 5, No. 1. pp. 29-43.
@article{34888fdd23e14662b3c8e761200fa63e,
title = "Molecular imaging and fusion targeted biopsy of the prostate",
abstract = "Purpose: This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods: Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50{\%} of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results: Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion: Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.",
keywords = "Image registration, Image segmentation, Magnetic resonance imaging (MRI), Molecular imaging, Positron emission tomography (PET), Prostate cancer, Targeted biopsy",
author = "Baowei Fei and Nieh, {Peter T.} and Master, {Viraj A.} and Yun Zhang and Osunkoya, {Adeboye O.} and Schuster, {David M.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1007/s40336-016-0214-7",
language = "English (US)",
volume = "5",
pages = "29--43",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Springer-Verlag Italia",
number = "1",

}

TY - JOUR

T1 - Molecular imaging and fusion targeted biopsy of the prostate

AU - Fei, Baowei

AU - Nieh, Peter T.

AU - Master, Viraj A.

AU - Zhang, Yun

AU - Osunkoya, Adeboye O.

AU - Schuster, David M.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Purpose: This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods: Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results: Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion: Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.

AB - Purpose: This paper provides a review on molecular imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) for prostate cancer detection and its applications in fusion targeted biopsy of the prostate. Methods: Literature search was performed through the PubMed database using the keywords “prostate cancer”, “MRI/ultrasound fusion”, “molecular imaging”, and “targeted biopsy”. Estimates in autopsy studies indicate that 50% of men older than 50 years of age have prostate cancer. Systematic transrectal ultrasound (TRUS) guided prostate biopsy is considered the standard method for prostate cancer detection and has a significant sampling error and a low sensitivity. Molecular imaging technology and new biopsy approaches are emerging to improve the detection of prostate cancer. Results: Molecular imaging with PET and MRI shows promising results in the early detection of prostate cancer. MRI/TRUS fusion targeted biopsy has become a new clinical standard for the diagnosis of prostate cancer. PET molecular image-directed, three-dimensional ultrasound-guided biopsy is a new technology that has great potential for improving prostate cancer detection rate and for distinguishing aggressive prostate cancer from indolent disease. Conclusion: Molecular imaging and fusion targeted biopsy are active research areas in prostate cancer research.

KW - Image registration

KW - Image segmentation

KW - Magnetic resonance imaging (MRI)

KW - Molecular imaging

KW - Positron emission tomography (PET)

KW - Prostate cancer

KW - Targeted biopsy

UR - http://www.scopus.com/inward/record.url?scp=85010702221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010702221&partnerID=8YFLogxK

U2 - 10.1007/s40336-016-0214-7

DO - 10.1007/s40336-016-0214-7

M3 - Review article

C2 - 28971090

AN - SCOPUS:85010702221

VL - 5

SP - 29

EP - 43

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 1

ER -